Review
Classical Hodgkin’s Lymphoma
In: The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies [Internet]. 8th edition. Cham (CH): Springer; 2024. Chapter 89.
.
Affiliations
- PMID: 39437089
- Bookshelf ID: NBK608336
- DOI: 10.1007/978-3-031-44080-9_89
Item in Clipboard
Review
Classical Hodgkin’s Lymphoma
Excerpt
HL is a malignancy arising from germinal centre or post-germinal centre B cells. The cancer cells form a minority of the tumour and are surrounded by a reactive inflammatory milieu comprising lymphocytes, eosinophils, neutrophils, histiocytes and plasma cells. These malignant cells can be pathognomonic, multinucleate giant cells or large mononuclear cells and, together, are referred to as Hodgkin and Reed–Sternberg (HRS) cells.
Copyright 2024, The Author(s).
Sections
- 89.1. Definition and Epidemiology
- 89.2. Diagnosis
- 89.3. Classification
- 89.4. Risk Factors
- 89.5. First-Line Treatment
- 89.6. Second-Line Treatment Before Auto-HCT
- 89.7. Autologous HCT
- 89.8. Tandem Auto-HCT
- 89.9. Disease Relapse After Auto-HCT
- 89.10. Allogeneic HCT
- 89.11. Therapeutic Algorithm Recommended by the Authors (Modified from Yethava et al.)
- 89.12. Long-Term Outcomes of Auto-HCT and Allo-HCT in Patients with Relapsed/Refractory cHL (EBMT Database, with Permission)
- References
References
-
- Ansell SM, Radford J, Connors JM, et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2022;387:310–20. - PubMed
-
- Bazarbachi A, Boumendil A, Finel H, et al. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. Br J Haematol. 2018;181:86–96. - PubMed
-
- Bazarbachi A, Boumendil A, Finel H, et al. The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. Leukemia. 2022;36:1646–53. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
